Cyclo Therapeutics announces publication of positive data from phase II clinical study of Trappsol Cyclo for the treatment of Niemann
Cyclo Therapeutics, Inc. announced the publication of positive data from its Phase 1/II clinical trial, which demonstrated promising safety and efficacy results for Trappsol Cyclo in the treatment of Niemann-Pick Disease Type C1, a rare, genetic disease causing cholesterol accumulation in cells, leading to dysfunction of the liver, lung, spleen and brain and premature death
The manuscript titled, “Long-term administration of intravenous Trappsol Cyclo (HP beta CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick Disease Type C1: Results of an international 48-week Phase I/II trial,” were published in the official journal of Molecular Genetics and Metabolism Reports.
“The data seen to-date provide support for the capacity of Trappsol Cyclo to alter the disease on a biochemical level, including in the central nervous system, and improve clinical signs and symptoms of NPC. In these Phase II data, all three doses of Trappsol Cyclo were well-tolerated overall with efficacy across multiple clinical endpoints of intravenous (IV) administration of Trappsol Cyclo. I am pleased with the progress we’ve made and remain committed to exploring the potential of Trappsol Cyclo as a potential life-changing medicine for the NPC community,” commented Caroline Hastings, MD, author of the published manuscript, Chair of the Company’s Phase III Trappsol Cyclo Program Steering Committee and Global Principal Investigator for the Company’s ongoing TransportNPC study evaluating Trappsol Cyclo for the treatment of NPC.
Trial completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS).
Cyclo Therapeutics continues to advance enrollment in its ongoing pivotal Phase III study, TransportNPC. The Phase III study intends to enroll approximately 93 pediatric and adult patients (age 3 years and older) with NPC1 and is now active in 12 countries. Enrollment is expected to be completed by the end of this year.
See- Molecular Genetics and Metabolism- "Long-term administration of intravenous Trappsol Cyclo results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial".- Reena Sharma, Caroline Hastings , Orna Staretz-Chacham , Julian Raiman et.al.,.Volume 36, September 2023, 100988.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins